Ravi Salgia to Ovarian Neoplasms
This is a "connection" page, showing publications Ravi Salgia has written about Ovarian Neoplasms.
Connection Strength
0.447
-
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023 11; 217:115847.
Score: 0.147
-
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039.
Score: 0.125
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
Score: 0.050
-
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):976-84.
Score: 0.049
-
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
Score: 0.046
-
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000 Mar 10; 275(10):6868-75.
Score: 0.029